These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8529484)

  • 1. The effects of metformin on cardiovascular risk factors.
    Grant PJ
    Diabetes Metab Rev; 1995 Sep; 11 Suppl 1():S43-50. PubMed ID: 8529484
    [No Abstract]   [Full Text] [Related]  

  • 2. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
    Palumbo PJ
    J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cardiovascular benefits of insulin sensitizers.
    Kunhiraman BP; Jawa A; Fonseca VA
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.
    Fonseca VA
    Am J Cardiol; 2003 Aug; 92(4A):50J-60J. PubMed ID: 12957327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of thiazolidinediones on cardiovascular risk factors.
    Gouda BP; Asnani S; Fonseca VA
    Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
    Kosegawa I; Katayama S; Kikuchi C; Kashiwabara H; Negishi K; Ishii J; Inukai K; Oka Y
    Hypertens Res; 1996 Mar; 19(1):37-41. PubMed ID: 8829822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of type II diabetes.
    Lombard L
    SADJ; 2005 Apr; 60(3):120-1. PubMed ID: 15901019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of metformin on haemostasis and vascular function in man.
    Grant PJ
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S44-52. PubMed ID: 14502100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
    Henry RR
    Clin Ther; 2003; 25 Suppl B():B47-63. PubMed ID: 14553866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integrated drug therapy of the metabolic syndrome].
    Julius U; Hanefeld M
    Internist (Berl); 1996 Jul; 37(7):722-30. PubMed ID: 8766266
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is metformin more than an oral hypoglycaemic agent?
    Vague P
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S5-7. PubMed ID: 14502095
    [No Abstract]   [Full Text] [Related]  

  • 13. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Satoh J
    Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Marcus AO
    Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.
    Hadigan C; Rabe J; Grinspoon S
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4611-5. PubMed ID: 12364443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk.
    Malin SK; Braun B
    Exerc Sport Sci Rev; 2016 Jan; 44(1):4-11. PubMed ID: 26583801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
    Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
    Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.